COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Biopsies and Polyps

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00835445
Recruitment Status : Completed
First Posted : February 3, 2009
Last Update Posted : January 7, 2011
Information provided by:
Laval University

Tracking Information
First Submitted Date January 30, 2009
First Posted Date February 3, 2009
Last Update Posted Date January 7, 2011
Study Start Date July 2007
Actual Primary Completion Date October 2008   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: February 2, 2009)
The primary endpoint will be the difference in expression of IL-5 in nasal polyps and normal mucosa biopsies from asthmatic and non asthmatic subjects. [ Time Frame: No time frame ]
Original Primary Outcome Measures Same as current
Change History
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title Biopsies and Polyps
Official Title Nasal Features of Subjects With Nasal Polyposis With or Without Asthma
Brief Summary

Background: Nasal polyps are found in about 5% of asthmatic patients.A close link exists between the upper and lower airways and the concept of the "United Airways" has emerged mainly from studies on allergic rhinitis and asthma. However, other upper airway diseases, such as chronic sinusitis and nasal polyposis may influence lower airway diseases. As for nasal polyposis, eosinophils are the major effector cells in asthma and have been associated with a worsening of this condition.

Aim: To compare normal nasal mucosa and nasal polyp biopsies from subjects with nasal polyposis with or without asthma.

Hypothesis: Nasal polyps from asthmatic subjects show a more aggressive pro-inflammatory pattern of cytokine expression compared to nasal polyps from non asthmatic subjects, and therefore contribute to the development and severity of asthma.

Detailed Description The study will include 2 visits separated by a maximum of 7 days. During the first visit, subjects' characteristics will be documented by a locally validated questionnaire. Allergy skin prick tests, spirometry, methacholine inhalation test and induced sputum will also be done. Asthma and rhinitis control will be evaluated by locally validated questionnaires, the Asthma Control Scoring System (ACSS) and the Rhinitis Control Scoring System (RCSS), respectively. Nasal peak inspiratory flow (NPIF) and oral peak expiratory flow (PEF) will also be recorded to obtain the nasal blockage index (NBI). On the second visit, nasal biopsies will be taken.
Study Type Observational
Study Design Observational Model: Case Control
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Retention:   Samples Without DNA
Nasal polyps (Biopsies) Normal nasal mucosa (Biopsies) Sputum
Sampling Method Non-Probability Sample
Study Population Recruited from the ENT clinic (Laval Hospital, Quebec City, Canada)
  • Nasal Polyps
  • Asthma
Intervention Not Provided
Study Groups/Cohorts
  • 1
    Asthmatics with polyps
  • 2
    Non-asthmatics with polyps
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: January 6, 2011)
Original Estimated Enrollment
 (submitted: February 2, 2009)
Actual Study Completion Date September 2009
Actual Primary Completion Date October 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

For all subjects:

  • Non smoking men or women aged 18 to 65 years old.
  • Subjects will have nasal polyps as defined above.

For asthmatic subjects:

  • Subjects will have a history consistent with asthma according to the criteria of the ATS[18] defined on the basis of episodic or persistent chest tightness, wheeze or cough in the past 6 months. At entry into the study, FEV1 will be over 70% predicted.
  • Asthma will have been stable for at least 3 months before entering the trial.
  • Asthma medication will have been stable for at least 1 month prior to the study.

For non asthmatic subjects:

  • A methacholine challenge test with a PC20 (provoking concentration of methacholine to cause a 20% fall in FEV1) over 16 mg/mL.

Exclusion Criteria:

For all subjects:

  • Smoking (current smoking) or ex-smoking (les than 6 months or history of more than 10 pack-year of smoking).
  • Use of anti-leukotriene medication within the last 3 months.
  • Use of systemic corticosteroids within the last 3 months.
  • Use of anti-coagulant therapy.
  • Recent (less than 1 month) upper or lower respiratory tract infection, any other condition that may interfere with the evaluations.
  • Pregnancy, breast-feeding or planned pregnancy during the study. Fertile woman not using acceptable contraceptive measures, as judged by the investigator.
  • Subjects unable to perform or with contraindications to the tests proposed.
  • Subjects who are, in the opinion of the investigator, mentally or legally incapacitated thus preventing informed consent from being obtained.

For asthmatic subjects:

  • Unstable asthma shown by respiratory symptoms and B2-agonists need more than 3 times/week and nocturnal asthma symptoms.
Sexes Eligible for Study: All
Ages 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Canada
Removed Location Countries  
Administrative Information
NCT Number NCT00835445
Other Study ID Numbers CER 20188
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Louis-Philippe Boulet, Hôpital Laval
Study Sponsor Laval University
Collaborators Not Provided
Principal Investigator: Louis-Philippe Boulet, MD Centre de recherche, Hôpital Laval
PRS Account Laval University
Verification Date December 2010